The Chinese NDRC targets price-related illegal conducts in the pharmaceutical sector

NDRC Targets Price-related Illegal Conducts in the Pharmaceutical Sector* On May 4, 2015, the NDRC published Notice on Reinforcing Supervision over Medical Prices (“Notice”). In the Notice, the NDRC issued a range of specific opinions on the supervision over medical price, including immediately launching special inspections into illegal conducts under Pricing law and AML and some other specific issues. In this article, we would analyze the antitrust issues which may occur in such special inspections, in order to provide advice for antitrust compliance in pharmaceutical sector. The Notice aims to implement the Opinions on Promoting the Drug Pricing Reform (“Opinion”), which was jointly published by the NDRC, the National Health and Family Planning Commission (“NHFPC”), the Ministry of

Access to this article is restricted to subscribers

Already Subscribed? Sign-in

Access to this article is restricted to subscribers.

Read one article for free

Sign-up to read this article for free and discover our services.

 

PDF Version

Authors

  • King & Wood Mallesons (Beijing)
  • Freshfields Bruckhaus Deringer (Beijing)

Quotation

Susan Ning, Hazel Yin, The Chinese NDRC targets price-related illegal conducts in the pharmaceutical sector, 4 May 2015, e-Competitions Bulletin Competition in the Pharmaceutical sector, Art. N° 73795

Visites 185

All issues

  • Latest News issue 
  • All News issues
  • Latest Special issue 
  • All Special issues